COMPLEXED PROSTATE SPECIFIC ANTIGEN (CPSA) ASSAY FOR THE BAYER ADVIA INTEGRATED MODULE SYSTEM

Prostate-specific Antigen (psa) For Management Of Prostate Cancers

BAYER CORP.

The following data is part of a premarket notification filed by Bayer Corp. with the FDA for Complexed Prostate Specific Antigen (cpsa) Assay For The Bayer Advia Integrated Module System.

Pre-market Notification Details

Device IDK022288
510k NumberK022288
Device Name:COMPLEXED PROSTATE SPECIFIC ANTIGEN (CPSA) ASSAY FOR THE BAYER ADVIA INTEGRATED MODULE SYSTEM
ClassificationProstate-specific Antigen (psa) For Management Of Prostate Cancers
Applicant BAYER CORP. 511 BENEDICT AVE. Tarrytown,  NY  10591 -5097
ContactKenneth T Edds
CorrespondentKenneth T Edds
BAYER CORP. 511 BENEDICT AVE. Tarrytown,  NY  10591 -5097
Product CodeLTJ  
CFR Regulation Number866.6010 [🔎]
DecisionSubstantially Equivalent (SESE)
TypeTraditional
3rd Party ReviewedNo
Combination ProductNo
Date Received2002-07-15
Decision Date2002-12-17
Summary:summary

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.